An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases - Wikidata - awgldk - TriplyDB

An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases

An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases

http://www.wikidata.org/entity/Q34187525

about

Precision medicine in spinocerebellar ataxias: treatment based on common mechanisms of disease Oligonucleotide-based strategies to combat polyglutamine diseases.Phosphorodiamidate morpholino oligomers suppress mutant huntingtin expression and attenuate neurotoxicity.Antisense therapy in neurology Aberrant RNA homeostasis in amyotrophic lateral sclerosis: potential for new therapeutic targets?The role of the immune system in triplet repeat expansion diseases Nuclear retention of full-length HTT RNA is mediated by splicing factors MBNL1 and U2AF65 Design and analysis of effects of triplet repeat oligonucleotides in cell models for myotonic dystrophy A brief history of triplet repeat diseases.Consensus paper: pathological mechanisms underlying neurodegeneration in spinocerebellar ataxias.Reduction of Huntington's Disease RNA Foci by CAG Repeat-Targeting Reagents.Small non-coding RNAs add complexity to the RNA pathogenic mechanisms in trinucleotide repeat expansion diseases.MicroRNAs and Molecular Mechanisms of Neurodegeneration.Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels.New Reasons to Pursue the Therapeutic Potential of Synthetic Nucleic Acids for Neurological Diseases.Self-duplexing CUG repeats selectively inhibit mutant huntingtin expression Influence of mismatched and bulged nucleotides on SNP-preferential RNase H cleavage of RNA-antisense gapmer heteroduplexes.Precise Excision of the CAG Tract from the Huntingtin Gene by Cas9 Nickases.Neurochemical abnormalities in premanifest and early spinocerebellar ataxias.RNAi-based therapies for Huntington’s disease: delivery challenges and opportunities

P2860

Q26764958-C4543911-B78D-4DBE-A919-7AE1A8308548 Q33791247-88A729EF-C53B-4D45-A4E0-B2E83830DA5C Q34463222-1AF832C1-F2A8-488F-8B4B-37879AB7A616 Q34608717-CBF45EF7-769E-4876-AC4A-2FEA844CF968 Q35019375-1B69D662-C6A8-488A-B577-A717DF21C176 Q35271805-57F444D2-96BA-43EE-984E-257CBA21F03A Q35896064-952A9251-E3FC-4677-8C62-62818657146C Q36738386-922154D2-7BD0-43CC-98A1-7F12225540CA Q37553564-5D9DDE6E-E7D0-47D9-B88A-D2C683482B7D Q37619548-ED484FED-B9B6-4411-8501-69EDAC5EB3BE Q37723428-702FE546-3138-4966-9057-592CCDEFA096 Q38172118-DAEA657F-C661-4555-8720-A28467615EE0 Q38202497-8D56B9AB-A4BA-4E4B-B780-AB99D76597DB Q38290349-201E7338-ACCB-4A99-82BB-C4BFE83AF6BB Q41652242-1F083E9C-D045-4320-972F-6C6F1FD849C0 Q41898404-CE10BBB5-CB86-4AD4-AD7C-9709ECF57482 Q42286258-599906D9-1352-4EDA-98A2-53932732BD69 Q52430802-4212CE8C-72B3-425D-8768-5972FB43D775 Q52633801-A6D44EED-EB98-4B06-BBB9-59E80067B8B2 Q56192358-F1D1F6CF-7064-4932-AF5B-BE945973E349

P2860

An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases

http://www.wikidata.org/entity/Q34187525

description

2012 nî lūn-bûn

@nan

2012 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մարտին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases

@ast

An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases

@en

An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases

@nl

type

label

An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases

@ast

An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases

@en

An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases

@nl

prefLabel

An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases

@ast

An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases

@en

An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases

@nl

P1433

Q34187525-B40AC91B-0FAA-43B8-8792-306B3BDF33C4

P1476

Q34187525-B3245AFE-79A3-493D-A82B-5AABE81E48FF

P2093

Q34187525-18945ED4-A08E-4DC4-9ECE-9B1DA33503A1

Q34187525-4F1E207F-4B9F-4CFB-914D-DAAD15675F77

Q34187525-74F2CCFA-595C-4444-A5E6-ED8495D0F466

Q34187525-A9A82BDB-3555-42E6-A14C-F53CB1AB2AB1

Q34187525-D6AD5756-1CA0-4700-801A-7FEA09868957

P2860

Q34187525-01D232A4-7199-4C89-8CD5-63C31522D238

Q34187525-0AE049DA-A9F7-46A7-8F39-99262EAC1164

Q34187525-1358EBA4-72A0-4163-863D-050B7ADC0AF4

Q34187525-1568E6F8-3C3C-41AC-A04E-59B686BEFC69

Q34187525-172FC88F-0A30-424C-A622-4E1B5EA33D7B

Q34187525-18E2ECC4-4CA0-4EB7-987B-FD060DA1CF82

Q34187525-2047D1A1-79CF-4936-8B36-40F3DBEC9CD8

Q34187525-22669D3F-3CC5-471B-979F-6FDD92D12C02

Q34187525-264EA5B4-4E60-46A0-B6FE-486057F967F4

Q34187525-2C859702-33BB-4855-91D5-8B3DA1B4774B

P2888

Q34187525-0A64EE86-7A14-48A1-8667-A7553738C40D

P304

Q34187525-376275A8-C3E1-4735-B5C7-2A5978902FDD

P31

Q34187525-E902A220-CC90-4170-993F-B313385E4EA5

P356

Q34187525-4DE4C043-ECCA-4B27-AB59-F8D2969C2478

P478

Q34187525-D39F0BAF-1465-4905-A3DB-59B8F9397982

P50

Q34187525-3778A0ED-D0DF-420F-8E39-03A002B6CB19

Q34187525-E9A21E51-51BD-44E4-A781-C09863CB71A3

P577

Q34187525-92B6B59B-2A41-4402-AB39-DBDF552854AB

P5875

Q34187525-611AA470-0949-4D8F-A280-274EFE783C7B

P6179

Q34187525-1682901C-5CAE-4651-A038-E8AAD7620498

P698

Q34187525-5EA8F8D4-F8E8-4556-AFB2-68A14CBC0EF3

P932

Q34187525-92B72029-5571-4F41-A038-850EC7E11CA3

P356

P1433

BMC Molecular Biology

P1476

An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases

@en

P2093

Agnieszka Mykowska

http://www.w3.org/2001/XMLSchema#string

Joanna P Wroblewska

http://www.w3.org/2001/XMLSchema#string

Joanna Wisniewska-Kruk

http://www.w3.org/2001/XMLSchema#string

Marta Olejniczak

http://www.w3.org/2001/XMLSchema#string

Pawel M Switonski

http://www.w3.org/2001/XMLSchema#string

P2860

CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup

Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps

A systematic analysis of the silencing effects of an active siRNA at all single-nucleotide mismatched target sites

Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells

Current prospects for RNA interference-based therapies

Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1

RNA toxicity is a component of ataxin-3 degeneration in Drosophila

Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion

Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice

P2888

P304

6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2199-13-6

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Agnieszka Fiszer

Włodzimierz Krzyżosiak

P577

2012-03-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221684237

http://www.w3.org/2001/XMLSchema#string

P6179

1043290837

http://www.w3.org/2001/XMLSchema#string

P698

22397573

http://www.w3.org/2001/XMLSchema#string

P932

3359213

http://www.w3.org/2001/XMLSchema#string